Gynecologic Oncology | 2019
Post hoc exploratory analysis of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma from the randomized, placebo-controlled phase III study ARIEL3: Effect of a deleterious germline or no germline BRCA mutation on efficacy
Abstract
Robert L. Coleman,1 Amit M. Oza,2 Domenica Lorusso,3 Carol Aghajanian,4 Ana Oaknin,5 Andrew Dean,6 Nicoletta Colombo,7 Johanne I. Weberpals,8 Andrew R. Clamp,9 Giovanni Scambia,3 Alexandra Leary,10 Robert W. Holloway,11 Margarita Amenedo Gancedo,12 Peter C. Fong,13 Jeffrey C. Goh,14 David M. O’Malley,15 Susana Banerjee,16 Sandra Goble,17 Terri Cameron,17 Jonathan A. Ledermann18 1The University of Texas MD Anderson Cancer Center, Houston, TX; 2Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; 3Fondazione Policlinico Universitario A. Gemelli IRCCS and MITO, Rome, Italy; 4Memorial Sloan Kettering Cancer Center, New York, NY; 5Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain; 6St John of God Subiaco Hospital, Subiaco, WA, Australia; 7European Institute of Oncology and University of Milan-Bicocca, Milan, Italy; 8Ottawa Hospital Research Institute, Ottawa, ON, Canada; 9The Christie NHS Foundation Trust and University of Manchester, Manchester, UK; 10Gustave Roussy Cancer Center, INSERM U981, and Groupe d Investigateurs Nationaux pour l Etude des Cancers Ovariens (GINECO), Villejuif, France; 11Florida Hospital Cancer Institute, Orlando, FL; 12Oncology Center of Galicia, La Coruña, Spain; 13Auckland City Hospital, Grafton, Auckland, New Zealand; 14Cancer Care Services, Royal Brisbane and Women’s Hospital, Herston, and University of Queensland, St Lucia, QLD, Australia; 15The Ohio State University, James Cancer Center, Columbus, OH; 16The Royal Marsden NHS Foundation Trust, London, UK; 17Clovis Oncology, Inc., Boulder, CO; 18UCL Cancer Institute and UCL Hospitals, London, UK Post Hoc Exploratory Analysis of Rucaparib in Patients with Platinum-Sensitive Recurrent Ovarian Carcinoma from the Randomized, Placebo-Controlled Phase 3 Study ARIEL3: Effect of a Deleterious Germline or No Germline BRCA Mutation on Efficacy and Safety